Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting

Media coverage

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	BioSpace
  Country	United States
  Date	11/10/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	PR Newswire
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	Morningstar.com
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	Yahoo! Finance
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	TickerTech.com
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam

• Title	Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose Escalation and Expansion Data at the Society for Immunotherapy of Cancer's 2020 Annual Meeting
  Media name/outlet	WFMZ-TV Online
  Country	United States
  Date	11/9/20
  Persons	Devalingam Mahalingam